Stone N N, Laudone V P, Fair W R, Fishman J
Urol Res. 1987;15(3):165-7. doi: 10.1007/BF00254430.
Human prostatic tissue and expressed prostatic secretions (EPS) from patients with benign prostatic hyperplasia (BPH) and prostate cancer were incubated with (1 beta 3H) androstenedione. The extent of aromatization was determined by measuring the transfer of 3H from the 1 beta position into water. The amount of 3H2O recovered corresponds to the estrogens formed. Tissue from 5 patients with BPH yielded 2.13 (+/- 1.05) pmol/mg protein/h while the EPS from the same patients yielded 727 fmol/mg protein/h. In patients with prostate cancer the mean formation of estrogens was 388 fmol/mg protein/h (+/- 75). 4-hydroxy-androstenedione, an aromatase inhibitor, successfully inhibited aromatization in BPH and prostate cancer 53-98%.
将良性前列腺增生（BPH）患者和前列腺癌患者的人前列腺组织及前列腺分泌液（EPS）与（1β 3H）雄烯二酮一起孵育。通过测量3H从1β位向水中的转移来确定芳香化程度。回收的3H2O量对应于形成的雌激素量。5例BPH患者的组织产生2.13（±1.05）pmol/mg蛋白质/小时，而同一患者的EPS产生727 fmol/mg蛋白质/小时。前列腺癌患者中雌激素的平均形成量为388 fmol/mg蛋白质/小时（±75）。芳香化酶抑制剂4-羟基雄烯二酮成功抑制了BPH和前列腺癌中53-98%的芳香化作用。
